Venous Thromboembolism: Using Evidence-based Guidelines for Selecting Acute and Extended Anticoagulant Therapy
Release Date: May 19, 2017
Expiration Date: May 31, 2018
Activity Type: Application-based
CE Credits: 1 hour (0.1 CEU), no partial credit for pharmacists
Activity Fee: Free of charge
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Accreditation for Physicians
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
This continuing education activity was planned to meet the needs of clinicians with an interest in venous thromboembolism (VTE), especially primary care providers, emergency room physicians, hospitalists, cardiologists, pulmonologists, vascular surgeons, hematologists, and pharmacists in hospitals and ambulatory care clinics who care for patients with VTE.
Activity Content
This activity begins with an overview of the epidemiology, risk factors, and diagnosis of venous thromboembolism (VTE), followed by a review of the safety and efficacy of the direct oral anticoagulants for the acute treatment and secondary prevention of VTE. Current evidence-based guideline recommendations will also be discussed.
Learning Objectives
After the conclusion of this application-based educational activity, participants should be able to- Discuss the epidemiology, risk factors, and diagnosis of VTE.
- Compare the safety and efficacy of the direct oral anticoagulants with traditional therapies.
- Apply key recommendations in the updated guidelines for the management of VTE.
Faculty
Rachel P. Rosovsky, M.D., M.P.H.
Assistant Physician
Department of Hematology/Oncology
Massachusetts General Hospital
Instructor in Medicine
Harvard Medical School
Boston, Massachusetts
Rachel P. Rosovsky, M.D., M.P.H., is an assistant physician in the Department of Hematology/Oncology at Massachusetts General Hospital (MGH) in Boston and an instructor in medicine at Harvard Medical School (HMS).
Dr. Rosovsky earned her undergraduate degree from the University of Pennsylvania, Doctor of Medicine degree from Harvard Medical School, and Master in Public Health degree from Harvard School of Public Health. She completed her residency at Brigham and Women’s Hospital and fellowship at the Dana Farber Cancer Institute, both in Boston. She is board certified in hematology and medical oncology. She is an expert and leader in the field of venous thromboembolism (VTE), and her clinical and research interest and expertise revolve around the evaluation and treatment of patients with this condition.
Dr. Rosovsky is on the Board of Directors of the National Pulmonary Embolism Response Team (PERT) Consortium, and she is Chair of the Consortium’s Education Committee. She recently helped establish a national educational series for PERT members to discuss the most up-to-date topics and controversies in the work up and treatment of VTE, as well as a monthly newsletter highlighting current evidence-based literature on VTE. Dr. Rosovsky also serves on the Executive Committee of the MGH PERT and is the creator and director of the MGH PERT multidisciplinary follow-up clinic, the goals of which are to improve the care of patients with pulmonary embolism as they transition from inpatient to outpatient setting, standardize follow-up protocols, increase patient satisfaction, and expand patient education.
Dr. Rosovsky is actively engaged in the education of medical students, residents and fellows. In addition to bedside teaching and supervision during outpatient clinics and inpatient rotations, she lectures at continuing medical education courses locally, nationally and internationally. Dr. Rosovsky is also actively involved in research, investigating the risks, diagnosis, and treatment of VTE and other benign hematological conditions. Past research includes an analysis of endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide and dexamethasone and a study of VTE risk in cancer patients with increased tissue factor particles who are treated with a low molecular weight heparin (LMWH). Currently, she is participating in an international study comparing a LMWH product with one of the new direct oral anticoagulants (DOACs) in cancer patients with acute VTE. She is also the co-principal investigator on a multicenter study investigating the safety and efficacy of treating low risk deep vein thrombosis and pulmonary embolism (PE) in an outpatient setting, and she is the national lead investigator for an evaluation of a DOAC for low risk PE patients. She is involved in creating a PERT registry and national database to assess current treatments and long-term outcomes in patients with VTE. Through lectures, research, and written works that include original articles, book chapters, and scholarly reviews, she seeks to improve the care of patients with VTE and advance the understanding and treatment of this medical condition.
Toby C. Trujillo, Pharm.D., BCPS-AQ Cardiology, FAHA, FCCP, Initiative Chair
Associate Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Clinical Specialist - Anticoagulation/Cardiology
University of Colorado Hospital
Aurora, Colorado
Toby C. Trujillo, Pharm.D., BCPS-AQ Cardiology, FAHA, FCCP, is Associate Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences in Aurora. He also is a clinical specialist in anticoagulation and cardiology at University of Colorado Hospital.
Dr. Trujillo earned his Bachelor of Science degree in biochemistry from the University of California, Davis and his Doctor of Pharmacy degree from the University of California, San Francisco, where he also completed a residency in pharmacy practice. He then went on to do a fellowship in cardiovascular pharmacotherapy at The University of Arizona. Dr. Trujillo is a board-certified pharmacotherapy specialist with added qualifications in cardiology.
In his current role, Dr. Trujillo is involved in the stewardship of antithrombotic medications across the UC Health system, which includes serving as co-chair of the anticoagulation subcommittee of the P&T committee, as well as coordinating and staffing the Inpatient Anticoagulation Thrombosis Management Service.
Dr. Trujillo has served in several capacities within multidisciplinary healthcare organizations, such as the American Heart Association, American College of Cardiology, and Society of Critical Care Medicine. He has also served on committees and in leadership positions within the American College of Clinical Pharmacy, currently as a member of the ACCP Board of Regents. Dr. Trujillo is often invited to speak on a national level, and he authored several articles and book chapters in the area of cardiovascular pharmacotherapy.
Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Guidelines for Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on presentations.
All faculty and planners for ASHP Advantage education activities are qualified and selected by ASHP Advantage and required to disclose any relevant financial relationships with commercial interests. ASHP Advantage identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity.
- Toby C. Trujillo, Pharm.D., BCPS-AQ Cardiology, FAHA, FCCP, declares he has served as a consultant for Bristol-Myers Squibb and Pfizer Alliance and Janssen Pharmaceuticals, Inc. (Faculty and Steering Committee)
- Alpesh Amin, M.D., MBA, FACC, MACP, SFHM, declares that he has served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb and Pfizer Alliance, and Portola Pharmaceuticals, Inc. (Steering Committee)
- All other faculty and planners report no financial relationships relevant to this activity.
Methods and CE Requirements
This is an online activity consisting of audio and slides, an assessment, and a course evaluation. Participants should claim CE credit for this home-study educational activity only if they have not claimed credit for the live activity. Participants must view the entire presentation, take the activity assessment (a minimum score of 70% is required), and complete the course evaluation to receive CE credit. The handout includes slides and the assessment for your reference.
To access the activity, click "Launch Presentation" below. On the last slide of the presentation you must click the “Close Activity and Process CE” button to link to ASHP’s elearning portal to complete the process for obtaining credit. Per ACPE, CPE credit must be claimed no later than 60 days from the date of the live activity or completion of a home-study activity. CPE credit will be reported directly to CPE Monitor.
Agenda
Venous Thromboembolism: Using Evidence-based Guidelines for Selecting Acute and Extended Anticoagulant Therapy
Rachel P. Rosovsky, M.D., M.P.H., and Toby C. Trujillo, Pharm.D., BCPS-AQ Cardiology, FAHA, FCCP, Initiative Chair
Launch Presentation (60 minutes)*
*Allow additional time to complete the assessment and evaluation.
